Transposagen announces partnering model for its exclusive patents covering rat models of oncology, autoimmune and inflammatory diseases and issuance of OncoRat(TM) registered trademark
(Thomson Reuters ONE) -
Transposagen's patents cover all genetically engineered rat models with a broad
range of valuable disease model phenotypes. Access to these models and
intellectual property are being offered to drug discovery companies solely
through comprehensive licensing and service partnerships
Lexington, KY, Apr. 20, 2015 (GLOBE NEWSWIRE) -- Transposagen, a world leader in
genome engineering technologies and services, announced the registration of its
trademark OncoRat(TM) by the USPTO, for use with rat models for oncology in
issued patent No. 8,722,964. OncoRat(TM) covers all genetically engineered rat
models with oncology phenotypes, regardless of the method used to create the rat
model (e.g. site-specific nucleases, homologous recombination, transposon
insertion, etc.).
Access to the creation and use of patented genetically engineered rat lines is
being offered solely through comprehensive genome engineering IP licensing and
service partnership agreements. Companies that partner with Transposagen will
also gain access to genome engineering intellectual property including
piggyBac(TM), NextGEN(TM) CRISPR and XTN(TM) TALEN technologies. Transposagen
will also perform services for its partners, including custom genetically
engineered cell lines, animal models as well as gene editing reagent kits. For
more on how it works please visit our Partnering page.
Another issued patent, No. 8,558,055, covers all genetically engineered rat
models with autoimmune or inflammatory diseases. Additional pending patents
include rats with severe combined immune deficiency (SCID), diabetes, obesity,
susceptibility to pain, and phenotypes that are the result of mutations in drug
transporter or drug metabolism genes. The phenotype patents also cover cells
derived from genetically engineered rat models with specific phenotypes,
screening methods, as well as assays and kits for drug discovery purposes.
Transposagen is the only company that has freedom to operate with both the
enabling genome engineering technologies and the rat phenotype patents.
Please contact us to discuss your custom partnership for access to full freedom
to operate and genome engineering services.
Jack Crawford M.Sc.
Director, Sales & Marketing
Transposagen Biopharmaceuticals
535 West Second St., Suite 10
Lexington, KY 40508
www.transposagenbio.com
jcrawford(at)transposagenbio.com
Cell: 315-351-9115
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Transposagen Biopharmaceuticals, Inc. via GlobeNewswire
[HUG#1912220]
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2015 - 10:00 Uhr
Sprache: Deutsch
News-ID 386793
Anzahl Zeichen: 3207
contact information:
Town:
Lexington
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 151 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Transposagen announces partnering model for its exclusive patents covering rat models of oncology, autoimmune and inflammatory diseases and issuance of OncoRat(TM) registered trademark"
steht unter der journalistisch-redaktionellen Verantwortung von
Transposagen Biopharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
